Aurora Cannabis upgraded by Canaccord Genuity
$ACB
Medicinal Chemicals and Botanical Products
Health Care
Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2024 | Buy | TD Cowen | |
| 2/9/2024 | Hold → Buy | Canaccord Genuity | |
| 9/21/2022 | Sell → Hold | Canaccord Genuity | |
| 6/24/2022 | Neutral → Overweight | Cantor Fitzgerald | |
| 6/6/2022 | Sell → Hold | Stifel | |
| 11/10/2021 | $9.60 → $10.75 | Neutral | Cantor Fitzgerald |
| 10/28/2021 | $9.50 → $9.60 | Neutral | Cantor Fitzgerald |
| 10/5/2021 | $8.30 → $9.50 | Neutral | Cantor Fitzgerald |
NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv
NASDAQ | TSX: ACB EDMONTON, AB, Aug. 12, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 14,855,306, representing 27.23% of Aurora's issued and outstanding common shares as of the record date. All of
NASDAQ | TSX: ACB Newly created directorship to be filled by Rajesh Uttamchandani EDMONTON, AB, May 15, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today the appointment of Rajesh Uttamchandani to the Company's Board of Directors (the "Board"), effective today. Mr. Uttamchandani joins the Board with notable expertise in strategy development, innovation, human capital and governance. His impressive career is characterized by executive level roles with leadin
NASDAQ | TSX: ACB Company Launches Internships at Manufacturing Facility in Leuna, Germany to Cultivate Future Leaders in the Medical Cannabis Industry EDMONTON, AB, Jan. 10, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to announce the launch of an internship program at Aurora's leading EU-GMP facility in Leuna, Germany. In partnership with Erfurt University of Applied Sciences, students of the Horticultural Crop Production course will gain valuable hands-on experience on-site and deepen their understanding of medical cannabis cultivation. Aurora's investment in future industry leaders is one of the ma
NASDAQ | TSX: ACB The collaboration aims to broaden access of premium medical cannabis products to Australian patients EDMONTON, AB, Dec. 17, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to announce a distribution partnership between The Entourage Effect and MedReleaf Australia. The Entourage Effect provides comprehensive distribution and support services to pharmacies in Australia and will serve as a wholesaler for MedReleaf Australia's leading portfolio of products under the CraftPlant, Aurora, and IndiMed brands, furthering the mission to expand access for Australian patients.
NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company Continues to Offer Greater Choice for Patients EDMONTON, AB, Nov. 26, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces developments in cannabis science from Aurora's world class research and genetics facility, Aurora Coast. With a continued focus on premium, science-driven insights, these latest innovations demonstrate Aurora's commitment to providing patients with ongoing access to superior product offerings on AuroraMedical.com. "A
NASDAQ | TSX: ACB Record Adjusted EBITDA1 of $10.1 Million, a YoY increase of 210%Quarterly Net Revenue1 up 29% YoY to $81.1 Million, with 41% growth in Global Medical CannabisRe-Affirms Target of Positive Free Cash Flow1 in the Quarter Ending December 31, 2024Maintains Strong Balance Sheet with ~$152 Million of Cash and a Debt-Free Cannabis Business2EDMONTON, AB, Nov. 6, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter fiscal 2025.
NASDAQ | TSX: ACB EDMONTON, AB, Oct. 24, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today announced today that it has scheduled a conference call to discuss the results for its second quarter 2025 on Wednesday, November 6, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the second quarter 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, November 6, 2024 TIME:
Delivers Positive Free Cash Flow1 of $6.5 MillionIncreases Total Quarterly Net Revenue1 by 12% YoY to $83.4 Million, Record Net Revenue1 of $47.2 Million in Global Medical Cannabis Generates Adjusted EBITDA1 of $4.9 Million, a YoY increase of 87%Ends the Fiscal Quarter with a Debt-Free Cannabis Business2 and a Cash Position of ~$182 Million EDMONTON, AB, Aug. 7, 2024 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the first quarter fiscal 2025.
SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)
SC 13G - AURORA CANNABIS INC (0001683541) (Subject)
SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)
6-K - AURORA CANNABIS INC (0001683541) (Filer)
6-K - AURORA CANNABIS INC (0001683541) (Filer)
6-K - AURORA CANNABIS INC (0001683541) (Filer)
TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy
Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy
Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold